Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.21)
# 3,645
Out of 5,182 analysts
18
Total ratings
31.25%
Success rate
-0.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $13.00 | +438.46% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $3.99 | +225.81% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $150 → $250 | $1.16 | +21,451.72% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $6.65 | +802.26% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $4.97 | +1,107.24% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $3.10 | +222.58% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.20 | +1,066.67% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.49 | +436.91% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $3,000 | $3.92 | +76,430.61% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $11.02 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.05 | +293.44% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $2.13 | +464,788,632.39% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $37.30 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.16 | +375.44% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $13.00
Upside: +438.46%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.99
Upside: +225.81%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150 → $250
Current: $1.16
Upside: +21,451.72%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.65
Upside: +802.26%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $4.97
Upside: +1,107.24%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.10
Upside: +222.58%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.20
Upside: +1,066.67%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.49
Upside: +436.91%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $3,000
Current: $3.92
Upside: +76,430.61%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.02
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $3.05
Upside: +293.44%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $2.13
Upside: +464,788,632.39%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $37.30
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.16
Upside: +375.44%